Novo Nordisk's Tug of War: Solid Operations, Stubborn Skepticism
Published on 08/06/2026 at 04:14 | Redaktion boerse-global.de
The numbers tell one story. The share price tells another. Novo Nordisk's second-quarter report landed with a curious split personality this week: operational metrics that beat expectations, yet a stock that keeps bleeding value. Shares closed Wednesday at 38.76 euros, down 13.28 percent over seven trading sessions, with the gap to January's 52-week high now approaching 30 percent. A brief intraday bounce of 2.45 percent to 39.33 euros on Wednesday did little to mask the broader trend.
The Pipeline Problem Overshadows the P&L
Revenue for the second quarter of 2026 came in at 78.488 billion Danish kroner, up 7 percent in constant currencies, while adjusted operating profit advanced 11 percent to 33.389 billion kroner. Yet Reuters reported the stock fell between 4 and 6 percent on Tuesday as investors zeroed in on the less flattering details buried beneath the headline numbers.
The company booked a non-cash impairment of 6.3 billion kroner against its development portfolio, with 4.0 billion kroner tied to monlunabant, the asset acquired through the Inversago Pharma deal. That was compounded by Friday's disclosure that the Phase 3 ZEUS trial for ziltivekimab had missed its primary endpoint on reducing major adverse cardiovascular events. The drug's failure to deliver despite expected IL-6 pathway inhibition represents a setback in Novo Nordisk's efforts to diversify beyond its diabetes and obesity franchises — a strategic imperative as Eli Lilly intensifies competitive pressure.
CEO Mike Doustdar moved quickly to address the damage, telling Reuters and Bloomberg that the company would accelerate internal R&D and evaluate targeted bolt-on acquisitions to shore up the pipeline. Sydbank struck a measured tone in an August 5 client note, acknowledging the solid underlying business while conceding that the trial data and writedowns had bruised sentiment around pipeline resilience.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Guidance: Better, But Far From Heroic
The one bright spot came from the outlook. Management lifted its full-year guidance on Tuesday, now projecting adjusted sales and operating profit growth between 0 and minus 6 percent in constant currencies — an improvement over the previous range of minus 4 to minus 12 percent. Mizuho Securities was unimpressed, calling the revision "not heroic" and pointing to the absence of genuine upside surprises in Wegovy pill sales as the primary driver of the negative market reaction.
The oral semaglutide version of Wegovy generated 3.22 billion kroner in quarterly revenue, narrowly missing the consensus estimate of 3.27 billion. Cumulative US prescriptions have reached five million, and the product gained European momentum in mid-July when the European Commission approved the once-daily 25-milligram tablet for weight management. Italy has since been confirmed as the first EU market to launch the oral formulation, with Germany expected to follow in the third quarter of 2026.
Legal Wins and Shareholder Moves
Novo Nordisk also secured a legal victory this week: a Dutch court in The Hague issued a preliminary injunction against Ceban Ziekenhuisfarmacie, halting distribution of an infringing copycat semaglutide nasal spray. While such rulings protect the franchise, they do little to resolve the fundamental growth questions surrounding the pill segment.
The buyback program continues apace, with 1.145 million B-shares repurchased between July 27 and August 3, bringing the cumulative total to 12.305 million shares for 3.73 billion kroner. The broader twelve-month program carries a 15 billion kroner envelope, and since February 4 the company has acquired roughly 27.06 million B-shares for 7.53 billion kroner. Management's willingness to deploy capital signals confidence in the current valuation — even if not all institutional investors share that view. Lazard Asset Management cut its position by 89.2 percent during the first quarter, retaining just 92,516 shares, while Glenmede Trust also trimmed its stake. A Sunday filing showed Lazard further reducing its ADR holdings.
Analysts Split, Technicals Oversold
Wall Street remains divided. BMO Capital reaffirmed a "Hold" rating with a $45 price target on August 3, while Jefferies maintained its own "Hold" with a 285 kroner target following the results. Morningstar's Karen Andersen held her fair value estimate of 311 kroner on August 2, characterizing the ZEUS failure as disappointing but only marginally relevant to the long-term thesis.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Technically, the stock sits in oversold territory with an RSI of 35.5, suggesting selling pressure may be nearing exhaustion. The distance from the 52-week high stands at 28.31 percent — a more meaningful gauge of market skepticism than any single session's move.
Investors now look toward the Capital Markets Day scheduled for September 20-21, where strategy and financial targets will face scrutiny, followed by third-quarter results due November 4. The question hanging over Copenhagen is whether management can present a credible vision that extends beyond the current narrative of operational competence undermined by pipeline disappointments and a guidance range that, even after revision, still contemplates a down year.
Ad
Novo Nordisk Stock: New Analysis - 6 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
